Hiroaki Mitsuya

发表

Immunologic studies of peripheral blood in a child with hypogammaglobulinemia. Suggested mechanism for the development of malignant B‐cell lymphoma

K. Yamaguchi, I. Matsuda, H. Tsuchiya, 1984, Cancer.

Massive IgE‐hyperimmunoglobulinemia and storage histiocytosis in Sézary syndrome: A postmortem study

H. Mitsuya, K. Takahashi, H. Miyayama, 1984, Cancer.

Rarity of microsatellite alterations inpatients with paroxysmal nocturnal haemoglobinuria

M. Sakaguchi, M. Kawakita, M. Hidaka, 2000, European journal of haematology.

3H9, a monoclonal antibody capable of discriminating neutrophilic from basophilic and eosinophilic granulocytes

H. Mitsuya, M. Hidaka, T. Kawaguchi, 2000, European journal of haematology.

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

H. Mitsuya, S. Broder, S Broder, 1986, Proceedings of the National Academy of Sciences of the United States of America.

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

D W Barry, H. Mitsuya, S. Broder, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex

H. Mitsuya, S. Broder, R. Yarchoan, 1990, The Lancet.

Molecular targets for AIDS therapy.

H. Mitsuya, S. Broder, R. Yarchoan, 1990, Science.

Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus.

E. De Clercq, H. Mitsuya, S. Broder, 1986, Biochemical and biophysical research communications.

Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.

M. Reitz, H. Mitsuya, S. Broder, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I).

M. Reitz, H. Mitsuya, S. Broder, 1984, Science.

Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.

D. Venzon, H. Mitsuya, Y. Maeda, 1998, The Journal of infectious diseases.

In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations

J. Weinstein, D. Norbeck, D. Kempf, 1992, Antimicrobial Agents and Chemotherapy.

Insertion of microRNA-125b-1, a human homologue of lin-4, into a rearranged immunoglobulin heavy chain gene locus in a patient with precursor B-cell acute lymphoblastic leukemia

N Asou, H. Mitsuya, T. Sonoki, 2005, Leukemia.

Conformationally locked nucleoside analogues. Synthesis of dideoxycarbocyclic nucleoside analogues structurally related to neplanocin C.

H. Mitsuya, M. Nicklaus, V. Marquez, 1994, Journal of medicinal chemistry.

Human immunodeficiency virus type 1 infection of H9 cells induces increased glucose transporter expression

L. Staudt, H. Mitsuya, I. Simpson, 1996, Journal of virology.

Expression of a zinc finger gene in HTLV-I- and HTLV-II-transformed cells.

H. Mitsuya, J. Wright, K. Gunter, 1990, Science.

Alterations in cytotoxic and helper T cell function after infection of T cell clones with human T cell leukemia virus, type I.

M. Reitz, H. Mitsuya, S. Broder, 1986, The Journal of clinical investigation.

Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.

S. Matsushita, H. Mitsuya, S. Broder, 1984, Science.

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine.

H. Mitsuya, S. Broder, C. Perno, 1989, Science.

Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype.

D. Venzon, H. Mitsuya, R. Husson, 1995, The Journal of pediatrics.

Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state.

M. Matsuoka, H. Mitsuya, M. Uchino, 2001, Blood.

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.

S. Broder, T. Shirasaka, H. Mitsuya, 1993, The Journal of clinical investigation.

Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido- 2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine

D. S. Webb, H. Mitsuya, S. Broder, 1989, The Journal of experimental medicine.

AIDS therapies.

S. Broder, R. Yarchoan, Hiroaki Mitsuya, 1988, Scientific American.

Configuration and expression of the T cell receptor beta chain gene in human T-lymphotrophic virus I-infected cells

M. Reitz, H. Mitsuya, S. Broder, 1986, The Journal of experimental medicine.

Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus

P. Bunn, H. Mitsuya, S. Broder, 1983, The Journal of experimental medicine.

The immunology of HIV infection: implications for therapy.

H. Mitsuya, S. Broder, R. Yarchoan, 1992, AIDS research and human retroviruses.

Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

S. Broder, J. Balzarini, D. Cooney, 1986, Biochemical pharmacology.

A novel type of factor XI deficiency showing compound genetic abnormalities: a nonsense mutation and an impaired transcription.

H. Mitsuya, Y. Komiyama, M. Hidaka, 2000, International journal of hematology.

Two cases showing clonal progression with full evolution from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome to myelodysplastic syndromes and leukemia.

M. Hidaka, T. Kawaguchi, S. Ishihara, 2000, International journal of hematology.

Immunologic issues in anti-retroviral therapy.

H. Mitsuya, S. Broder, R. Yarchoan, 1990, Immunology today.

A Conserved Hydrogen-Bonding Network of P2 bis-Tetrahydrofuran-Containing HIV-1 Protease Inhibitors (PIs) with a Protease Active-Site Amino Acid Backbone Aids in Their Activity against PI-Resistant HIV

Arun K. Ghosh, P. Wingfield, J. Kaufman, 2014, Antimicrobial Agents and Chemotherapy.

Overview of the preclinical development of an antiretroviral drug, 2',3'-dideoxyinosine.

H. Mitsuya, S. Broder, J. Tomaszewski, 1990, Reviews of infectious diseases.

Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides.

H. Mitsuya, S. Broder, S. Aaronson, 1987, Proceedings of the National Academy of Sciences of the United States of America.